See the DrugPatentWatch profile for cosentyx

Based on the information available, there is no definitive answer as to whether the MMR (measles, mumps, and rubella) vaccine should be delayed while on Cosentyx (secukinumab). However, it is important to note that Cosentyx is a medication used to treat several immune-mediated inflammatory diseases, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It works by selectively inhibiting IL-17A, a cytokine involved in inflammatory processes [1].

On the other hand, the MMR vaccine is a live attenuated vaccine, which means it contains weakened forms of the measles, mumps, and rubella viruses [2]. The Centers for Disease Control and Prevention (CDC) recommends that most children get the MMR vaccine when they are 12-15 months old and again when they are 4-6 years old [2].

Regarding the interaction between Cosentyx and live vaccines, DrugPatentWatch.com states that "live vaccines are generally not recommended during treatment with biologic agents, including secukinumab (Cosentyx)" [3]. However, it is essential to consult with a healthcare provider to make an informed decision based on individual circumstances and medical history.

In summary, while there is no definitive answer as to whether the MMR vaccine should be delayed while on Cosentyx, it is generally recommended to avoid live vaccines during treatment with biologic agents. Consult with a healthcare provider for personalized advice.

Sources:
[1] Cosentyx (secukinumab) [Prescribing Information]. (2021). Novartis Pharmaceuticals Corporation. Retrieved from <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>
[2] Measles, Mumps, and Rubella (MMR) Vaccine. (2021). Centers for Disease Control and Prevention. Retrieved from <https://www.cdc.gov/vaccines/vpd/mmr/public/index.html>
[3] DrugPatentWatch. Cosentyx (secukinumab) Drug Profile. Retrieved from <https://www.drugpatentwatch.com/drugs/cosentyx>